Bispecific Antibody Shows Promise in R/R Multiple Myeloma
Teclistamab, a bispecific antibody that binds B-cell maturation antigen (BCMA) and CD3 to redirect T cells to multiple myeloma cells, showed promising efficacy in patients with relapsed or refractory disease, according to results from a phase I study. Forty patients received the recommended phase II dose of subcutaneous teclistamab, which led to an overall response […]